Evidence map›Paper›PMID 42547543›Full record

ArticleNature chemical biology2026

Computational design of antimicrobial peptide nanopores.

Rahul Deb, Marcelo D T Torres, Ivo Kabelka, Jan Přibyl, Kateřina Dvořáková Bendová, Edo Vreeker, Markéta Koběrská, Gabriela Balíková Novotná, Miloš Petřík, Giovanni Maglia and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rahul DebCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-2733-7012
Marcelo D T TorresMachine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ivo KabelkaCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Jan PřibylCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0003-1232-3694
Kateřina Dvořáková BendováInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Edo VreekerGroningen Biomolecular Science and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0003-4198-6745
Markéta KoběrskáInstitute of Microbiology, Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic.
Gabriela Balíková NovotnáInstitute of Microbiology, Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic.ORCID http://orcid.org/0000-0002-5464-4763
Miloš PetříkInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
Giovanni MagliaGroningen Biomolecular Science and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0003-2784-0811
Cesar de la Fuente-NunezMachine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Robert VáchaCentral European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. robert.vacha@muni.cz.ORCID http://orcid.org/0000-0001-7610-658X

Funding

Combining chemical and computational tools for predictive models of microbiome communitiesR35GM138201 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DE LA FUENTE, CESAR · 2020 to 2024
$1.8M
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101001470Grantová Agentura České Republiky (Grant Agency of the Czech Republic) GA20-20152SMinisterstvo Školství, Mládeže a Telovýchovy (Ministry of Education, Youth and Sports) CZ.02.01.01/00/22_008/0004597Ministerstvo Školství, Mládeže a Telovýchovy (Ministry of Education, Youth and Sports) CZ.02.1.01/0.0/0.0/16_019/0000868Ministerstvo Školství, Mládeže a Telovýchovy (Ministry of Education, Youth and Sports) LM2023042Ministerstvo Školství, Mládeže a Telovýchovy (Ministry of Education, Youth and Sports) LUC24105Technologická Agentura České Republiky (Technological Agency of the Czech Republic) TG02010067United States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1-21-1-0014U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35GM138201
6 · The paper itself

Abstract

Antibiotic resistance is a global health threat, driving the need for new molecules that kill bacteria via nontraditional mechanisms. Here, we present a computational de novo design strategy for α-helical peptides that self-assemble into large, stable and membrane-spanning nanopores with antimicrobial activity, including in vivo efficacy against drug-resistant pathogens. Molecular dynamics simulations guided the selection of sequences for transmembrane barrel-stave pore formation, which were validated by microscopy, electrophysiology and fluorescence assays. Using computational and experimental analyses, including negative design controls, we developed general design guidelines and 52 modular sequence templates with tunable antimicrobial, pore-forming properties. Mechanistic studies confirmed bacterial cytoplasmic membrane disruption via designed nanopore formation. A tuned lead peptide selectively killed drug-resistant ESKAPEE bacteria, including Acinetobacter baumannii, without harming human cells, and showed anti-infective efficacy in preclinical mouse infection models. The framework presented here enables the design of synthetic peptide nanopores for precision antimicrobials, anticancer agents, molecular sensors and delivery systems.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.